Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

101.56 +1.77 (+1.78%)
Streaming Delayed Price Updated: 1:37 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 605,335
Open 99.58
Bid (Size) 101.52 (100)
Ask (Size) 101.60 (200)
Prev. Close 99.79
Today's Range 98.38 - 101.86
52wk Range 29.17 - 124.49
Shares Outstanding 106,313,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise... 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+28.5%
+28.5%
1 Month
-12.6%
-12.6%
3 Month
+44.0%
+44.0%
6 Month
+180.9%
+180.9%
1 Year
+144.9%
+144.9%

More News

Read More
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗
Via Stocktwits
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Via The Motley Fool
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗
Via The Motley Fool
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
Via Finterra
Topics Economy Initial Public Offering
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗
Via Benzinga
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Economy Stocks
News headline image
Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗
Via Stocktwits
News headline image
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗
Via Stocktwits
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Why Revolution Medicines Stock Surged by 11% Today ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗
Via Benzinga
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?
Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.
What exchange does Revolution Medicines, Inc. - Common Stock trade on?
Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?
The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market
What is the current price of Revolution Medicines, Inc. - Common Stock?
The current price of Revolution Medicines, Inc. - Common Stock is 101.56
When was Revolution Medicines, Inc. - Common Stock last traded?
The last trade of Revolution Medicines, Inc. - Common Stock was at 02/19/26 01:37 PM ET
What is the market capitalization of Revolution Medicines, Inc. - Common Stock?
The market capitalization of Revolution Medicines, Inc. - Common Stock is 10.80B
How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?
Revolution Medicines, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.